MSCLF News and Press, Satellos Bioscience Inc. From 05/13/25

urban-gro Inc. (UGRO) is expected to report for quarter end 2025-03-31 Karman Holdings Inc. (KRMN) is expected to report $0.02 for Q1 2025 PyroGenesis Inc Com (PYRGF) is expected to report for quarter end 2025-03-31 GeoVax Labs Inc. (GOVX) is expected to report $-0.59 for Q1 2025 ...

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company” ), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, will present at the CureDuchenne FUTURES National Conference, ...

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company” ), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, will present at the 2025 Bloom Burton & Co. Healthcare Inv...

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company” ), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, will present and participate at the following investor confere...

Nu Ride Inc. - Class A (NRDE) is expected to report for quarter end 2024-12-31 Dalrada Financial Corp. (DFCO) is expected to report for quarter end 2024-12-31 HilleVax Inc. (HLVX) is expected to report $-0.38 for Q4 2024 Chewy Inc. Class A (CHWY) is expected to report $0.03 for Q4 202...

– Completed enrollment and dosing in a Phase 1a clinical trial in 72 healthy volunteers to assess safety and pharmacokinetic (PK) properties of SAT-3247 – Presented initial Phase 1a data at Muscular Dystrophy Association (MDA) Clinical & Scientific Conference sho...

- Phase 1a data shows SAT-3247 was safe and well tolerated in 72 healthy volunteers after both single and repeated administration - Phase 1a data shows favorable pharmacokinetic (PK) profile of SAT-3247, reinforcing its potential as a first-of-its-kind oral therapy for Duchenne Mu...

- Satellos plans to highlight Phase 1 safety and PK data for SAT-3247 Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“ Satellos ” or the “ Company ”), a public biotech company developing new small molecule therapeutic approach...

- Company remains on track to report Phase 1a data from both the Single- and Multiple-Ascending Dose (SAD and MAD) cohorts in the healthy volunteer portion of the study in 1Q 2025 at an upcoming major medical meeting - The Phase 1b portion of the trial, in DMD patients, is underway with the i...

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“ Satellos ” or the “ Company ”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that managemen...